blood test program Articles
1 articles found
-
INOVIQ study validates the use of SubB2M as an aid in diagnosing malignant melanoma
Data from 144 tissue samples in the feasibility study demonstrated that SubB2M immunohistochemistry detected melanoma with 91% sensitivity and discriminated between malignant melanoma and benign skin lesions. SubB2M-based immunohistochemistry applications represent a new product opportunity for SubB2M in the $1.9b immunohistochemistry market. INOVIQ Ltd (ASX:IIQ) has successfully completed ...
By INOVIQ Ltd
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you